Field Notes.

October 31, 2026

Avenda’s Unfold AI Is Moving Into the Operating Room. Its Evidence Stops at the Pathology Lab.

Avenda Health is bringing its Unfold AI prostate cancer map into the operating room, citing research that predicts fewer positive margins. That research compared the map with pathology after surgery, and its authors say the prospective study is still being planned.

October 30, 2026

How a Section 232 Finding on Robots Becomes a Tariff, and What the 180 Days Are For

The October 28 Section 232 proclamation on robotics and industrial machinery orders 180 days of trade talks and keeps tariffs, quotas and fees available afterward. It covers parts and components, so a robot builder's risk sits in the gears, sensors and encoders it buys abroad.

October 29, 2026

Boston Scientific’s Watchman Trial Met Its Goal. It Studied the Patients Boston Wants Next.

US Watchman sales fell 7% last quarter and standalone procedures dropped by a high-teens percentage, seven months after Boston Scientific's own CHAMPION-AF trial met its goal. That trial enrolled patients who could take blood thinners. CLOSURE-AF, run independently on older patients at high bleeding risk, found closing the appendage did worse than best medical care.

October 28, 2026

ANYbotics’ ANYmal X Is Certified for Explosive Plants. The Certificate Says Which Ones.

ANYbotics began delivering ANYmal X, a legged inspection robot certified for the explosive areas of oil, gas and chemical plants. Its ATEX rating covers Zones 1 and 2, Gas Group IIB and T4, which leaves hydrogen areas out, and its international certificate waits on an audit of the production line.

October 27, 2026

Zoll Bought Its Circuit Boards Through Contract Manufacturers. In a Chip Shortage, That Hides You.

Zoll's chairman told AdvaMed's conference that AI data centers are competing with medtech for chips, and that Zoll used to buy its boards through contract manufacturers with no direct tie to the chip suppliers. A startup building that way is in the same spot at a smaller size, and its cheapest protection is knowing its single-source parts and the people who supply them.

October 26, 2026

Olympus’s Risk Report Left Out Hazards Its Own Complaint Files Had Found

The FDA's October warning letter to Olympus found a risk report that left out air embolism and patient death after a confirmed death, though the company's own complaint investigations had identified those hazards. The same gap can open in a small hardware company, and it is cheapest to close before the first unit ships.

October 25, 2026

bioMérieux’s Vaginitis Test Won a CLIA Waiver. The Operator Was a Design Input.

bioMérieux's SpotFire vaginitis panel won a dual 510(k) clearance and CLIA waiver, announced October 22. The FDA's study rules for a waiver describe the person who will run the test, so choosing that person is a design decision made long before the filing.